STOCK TITAN

Calidi Biotherapeutics Inc - CLDI STOCK NEWS

Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.

About Calidi Biotherapeutics Inc.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of immuno-oncology, leveraging cutting-edge stem cell-based platforms to revolutionize cancer treatment. Headquartered in San Diego, California, Calidi specializes in developing proprietary technologies that utilize potent allogeneic stem cells to deliver and enhance the efficacy of oncolytic viruses, targeting a range of oncology indications, including high-grade gliomas and solid tumors.

Innovative Stem Cell-Based Platforms

Calidi's core innovation lies in its unique, off-the-shelf, universal cell-based delivery platforms. These platforms are designed to protect, amplify, and potentiate oncolytic viruses, significantly improving therapeutic outcomes while ensuring patient safety. The company's dual approach includes localized therapies, such as its CLD-101 platform for high-grade gliomas, and systemic therapies, like RTNova, which targets metastatic cancers. By addressing both localized and advanced-stage cancers, Calidi aims to overcome critical challenges in oncology, including the rapid immune clearance of virotherapies and limited therapeutic targeting.

Clinical and Preclinical Programs

Calidi is advancing a robust pipeline of clinical-stage and preclinical candidates. Its CLD-101 platform, utilizing neural stem cells loaded with oncolytic adenoviruses, is undergoing Phase 1b/2 trials for high-grade glioma at Northwestern University. Early studies have demonstrated safety, feasibility, and promising anti-tumor immune responses, paving the way for transformative outcomes in brain cancer treatment. The RTNova platform, on the other hand, represents a breakthrough in systemic virotherapy, leveraging extracellular enveloped viruses (EEVs) to target multiple metastatic tumor sites while avoiding rapid immune clearance.

Regenerative Medicine and Beyond

In addition to oncology, Calidi is exploring the potential of its stem cell technologies in regenerative medicine through its Nova Cell subsidiary. This strategic expansion taps into the growing global demand for stem cell therapies, targeting applications in cosmetics, orthopedics, autoimmune diseases, and more. With a proprietary cell expansion method and specialized media, Calidi's approach offers significant scalability advantages over conventional mesenchymal stem cell lines.

Position in the Competitive Landscape

Operating within the rapidly evolving biotech industry, Calidi differentiates itself through its proprietary stem cell-based delivery platforms and dual therapeutic strategies. While competitors in the immuno-oncology space also focus on oncolytic virotherapies, Calidi's integration of stem cell technology enhances the safety, efficacy, and scalability of its treatments, positioning it as a potential leader in this niche. The company's strong intellectual property portfolio and strategic collaborations further bolster its competitive edge.

Commitment to Innovation and Patient Outcomes

Calidi Biotherapeutics is committed to addressing some of the most challenging cancers and unmet medical needs. Through its innovative platforms and ongoing clinical trials, the company aims to redefine how cancer is treated, offering hope to patients with limited therapeutic options. By combining scientific rigor with a focus on scalability and safety, Calidi is poised to make significant contributions to the fields of oncology and regenerative medicine.

Rhea-AI Summary
Calidi Biotherapeutics, Inc. (CLDI) has successfully closed a public offering, raising $6.1 million through the issuance of common stock and warrants. The offering included 15,197,500 shares at an effective price of $0.40 per share. The company plans to utilize the proceeds for working capital, general corporate purposes, pre-clinical and clinical trials, and debt repayment. Ladenburg Thalmann & Co. Inc. served as the placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
-
Rhea-AI Summary
Calidi Biotherapeutics, Inc. (CLDI) announces the pricing of a $6.1 million public offering, consisting of common stock and warrants, to fund its immunotherapy development. The offering includes 15,197,500 shares at $0.40 per share, with various warrant types. The gross proceeds are approximately $6.1 million before expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-65.5%
Tags
-
Rhea-AI Summary
Calidi Biotherapeutics presents new data at AACR Annual Meeting 2024 showcasing the immunomodulatory role of stem cells in antitumor virotherapies. The company's platforms CLD-101 and CLD-201 aim to enhance antitumor activity through innovative stem cell technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
62.37%
Tags
none
Rhea-AI Summary
Calidi Biotherapeutics Inc. (CLDI) receives $5.3 million grant from CIRM to develop ovarian cancer treatment using NeuroNova. The company introduces RTNova platform for diverse tumors, appoints new board members, and secures a new patent for SuperNova technology. Financially, Calidi reports a net loss for Q4 2023 and full-year 2023, with increased research and development expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
-
Rhea-AI Summary
City of Hope receives $5.3 million grant from CIRM to develop a treatment for metastatic ovarian cancer using Calidi's CLD-101. The grant supports preclinical translational studies, product manufacturing, and clinical trial design. CLD-101 utilizes neural stem cells to deliver an oncolytic adenovirus to tumor sites, showing promising results in chemo-resistant ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
-
Rhea-AI Summary
Calidi Biotherapeutics, Inc. (CLDI) announces the development of a systemic enveloped oncolytic virotherapy platform targeting a broad range of advanced tumor types. The therapy shows promising potential in transforming tumor immune microenvironments, eradicating diverse tumors, and synergizing with other immunotherapies. Preclinical models have demonstrated efficacy in resisting virus inactivation by human serum and targeting various tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
conferences
Rhea-AI Summary
Calidi Biotherapeutics, Inc. (CLDI) announced the appointment of three new members to its Scientific and Medical Advisory Board. These experts in oncology will support the development of novel immunotherapies targeting high-grade gliomas and solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
management
-
Rhea-AI Summary
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) announced presentations on its NeuroNova and SuperNova allogeneic stem cell-based virotherapy platforms at the 8th Oncolytic Virotherapy Summit, including updates on clinical trials and plans for advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
-
Rhea-AI Summary
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) announced the appointment of David LaPré to the company’s Board of Directors effective January 1, 2024. The company also announced the resignation of Director Alfonso Zulueta effective November 29, 2023 and the resignation of Director Tom Vecchiolla effective January 1, 2024. David LaPré brings a wealth of pharmaceutical industry experience and expertise, having held senior executive roles at Roche/Genentech for over 20 years. Calidi CEO Allan Camaisa expressed confidence in LaPré's ability to advance the company's cancer immunotherapies into later stage clinical trials. Calidi Biotherapeutics is focused on delivering effective allogeneic stem cell therapies to patient populations with few effective treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Calidi Biotherapeutics, Inc. (NYSE American: CLDI) announced the issuance of a new patent for its SuperNova technology, strengthening its intellectual property portfolio and positioning the company to advance its CLD-201 program into the clinic. The USPTO has issued U.S. Patent No. 11,655,455 titled, 'Enhanced systems for cell-mediated oncolytic viral therapy,' directed to Calidi’s SuperNova platform. This patent represents an important milestone for Calidi as it prepares to advance CLD-201 into the clinic. The patent covers a composition where cells are incubated with an oncolytic virus for a defined period, allowing the expression of at least one immunomodulatory protein or recombinant therapeutic protein encoded by the virus. Calidi also provided updates on the timing for certain anticipated clinical milestones for its NeuroNova and SuperNova platforms, with the first patient dosed in CLD-101 (NeuroNova) Phase 1b/2 trial in collaboration with Northwestern University anticipated in 1H 2024, and the first patient dosed in CLD-201 (SuperNova) Phase 1 trial anticipated in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none

FAQ

What is the current stock price of Calidi Biotherapeutics (CLDI)?

The current stock price of Calidi Biotherapeutics (CLDI) is $0.581 as of April 2, 2025.

What is the market cap of Calidi Biotherapeutics (CLDI)?

The market cap of Calidi Biotherapeutics (CLDI) is approximately 14.8M.

What does Calidi Biotherapeutics specialize in?

Calidi Biotherapeutics specializes in developing stem cell-based platforms for delivering and enhancing oncolytic virotherapies to treat cancers like high-grade gliomas and solid tumors.

What is unique about Calidi's technology?

Calidi's technology integrates allogeneic stem cells with oncolytic viruses, offering enhanced safety, efficacy, and scalability for both localized and systemic cancer therapies.

What are Calidi's key clinical programs?

Calidi's key programs include CLD-101 for high-grade gliomas and RTNova for systemic treatment of metastatic cancers, both of which are in advanced clinical development stages.

How does Calidi address metastatic cancers?

Calidi's RTNova platform uses extracellular enveloped viruses (EEVs) to target multiple metastatic tumor sites while avoiding rapid immune clearance, offering a systemic approach to advanced cancers.

What other applications does Calidi's technology have?

Beyond oncology, Calidi's stem cell platforms are being explored for regenerative medicine applications, including cosmetics, orthopedics, and autoimmune diseases through its Nova Cell subsidiary.

Where is Calidi Biotherapeutics headquartered?

Calidi Biotherapeutics is headquartered in San Diego, California.

What challenges does Calidi face in its market?

As a clinical-stage biotech company, Calidi faces challenges such as regulatory hurdles, securing funding, and differentiating itself in a competitive immuno-oncology landscape.

How does Calidi's technology improve patient safety?

Calidi's stem cell-based platforms protect and amplify oncolytic viruses, reducing potential side effects and enhancing therapeutic outcomes for patients.
Calidi Biotherapeutics Inc

NYSE:CLDI

CLDI Rankings

CLDI Stock Data

14.82M
26.29M
7.88%
4.06%
2.99%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO